AC
RCUS icon

AXQ Capital’s Arcus Biosciences RCUS Stock Holding History

AXQ Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,761
Closed -$160K – 657
2024
Q4 		$160K Buy
+10,761
New +$176K 0.07% 351
2023
Q1 		– Sell
-11,490
Closed -$238K – 613
2022
Q4 		$238K Buy
+11,490
New +$316K 0.17% 229

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

AXQ Capital's RCUS Position: Q1 2025 in Review

AXQ Capital sold out of Arcus Biosciences (RCUS) in Q1 2025, closing a stake of 10,761 shares — an estimated $160K sold.

AXQ Capital first reported a position in RCUS in Q4 2022 and held it in 2 quarters. The position peaked at $238K in Q4 2022. 186 funds tracked by Wall St. Rank hold RCUS as of Q1 2025.

  • AXQ Capital reported no remaining Arcus Biosciences position as of Q1 2025 after selling out during the quarter.
  • AXQ Capital sold 10,761 Arcus Biosciences shares in Q1 2025, an estimated $160K.
  • AXQ Capital first reported a position in Arcus Biosciences in Q4 2022 and held it in 2 quarters.
  • AXQ Capital's Arcus Biosciences position peaked at $238K in Q4 2022.
  • 186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2025.

Based on AXQ Capital's 13F filing for Q1 2025, filed 13 May 2025.